SUMMARY
The effects of the use of 2% topic Dorzolamide, a carbonic anhydrase inhibitor, were observed in 22 eyes (11 patients), with emphasis on the IOP, corrected visual acuity and perimetry, and its side effects on the cornea, conjuntiva, anterior chamber, lens, fundus and clinical and laboratorial exams (blood count, sodium and potassium). There was a decrease of 26,8% in IOP after 30 days of treatment, with persistence of this effect during a period of one year. Six patients had an deteriotation of the perimetry, and in three of them it was inespecific. There was no significant variation on the mean visual acuity during treatment. Mild side effects were observed in a few patients, but they were not found in subsequent examination. There was no laboratorial changes in the patients studied.